000			01684 a2200445 4500
005			20250516001926.0
264		0	_c20110126
008			201101s 0 0 eng d
022			_a1531-8257
024	7		_a10.1002/mds.23172 _2doi
040			_aNLM _beng _cNLM
100	1		_aJohnston, Tom H
245	0	0	_aThe α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. _h[electronic resource]
260			_bMovement disorders : official journal of the Movement Disorder Society _cOct 2010
300			_a2084-93 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdrenergic alpha-2 Receptor Antagonists _xpharmacology
650	0	4	_aAnalysis of Variance
650	0	4	_aAnimals
650	0	4	_aDisability Evaluation
650	0	4	_aDisease Models, Animal
650	0	4	_aDopamine Agents _xadverse effects
650	0	4	_aDrug Therapy, Combination _xmethods
650	0	4	_aDyskinesia, Drug-Induced _xdrug therapy
650	0	4	_aFemale
650	0	4	_aImidazoles _xpharmacology
650	0	4	_aIndans _xpharmacology
650	0	4	_aLevodopa _xadverse effects
650	0	4	_aMacaca fascicularis
650	0	4	_aMale
650	0	4	_aMotor Activity _xdrug effects
650	0	4	_aParkinsonian Disorders _xdrug therapy
650	0	4	_aTime Factors
700	1		_aFox, Susan H
700	1		_aPiggott, Matthew J
700	1		_aSavola, Juha-Matti
700	1		_aBrotchie, Jonathan M
773	0		_tMovement disorders : official journal of the Movement Disorder Society _gvol. 25 _gno. 13 _gp. 2084-93
856	4	0	_uhttps://doi.org/10.1002/mds.23172 _zAvailable from publisher's website
999			_c20157132 _d20157132